Skip to main content
Gut logoLink to Gut
. 2005 Nov;54(11):1523–1526. doi: 10.1136/gut.2005.072876

Mortality from cirrhosis: lack of progress over the last 35 years

C Gluud
PMCID: PMC1774736  PMID: 16227356

The findings of Roberts and colleagues1 in this issue of Gut show a lack of improvement in liver cirrhosis mortality during the years 1968 to 1999 (see page 1615). This must be provoking, disappointing, and sobering reading for many.

Roberts and colleagues1 based their findings on 8192 patients admitted to hospitals in the Oxford region of Southern England. The analyses were based on discharge and death certificate statistics. One year after admittance, the mortality rate was 34%, and remained so during the entire 30 year observation period. One year after admittance, the standardised mortality rate was 16.3 times that of the general population. These findings were robust to different analytical strategies. The disappointing results during the 30 year period were obtained both for the total group of 8192 patient admissions as well as for the diagnostic subgroups individually. The data show how deadly liver cirrhosis has been and continues to be.

Why does cirrhosis mortality remain unaffected despite our impression that it is decreasing? We expect decreasing mortality due to the use of many new interventions. Interventions such as liver transplantation,2 endoscopic treatment for bleeding varices,3,4 prevention of bleeding and rebleeding from varices with beta blockers,3,4 antiviral drugs for hepatitis B or C,5,6 and antibiotics for preventing and treating complications to cirrhosis,3,7–9 have all been introduced during the study period.

Three major causes may explain the contrast between the finding of no significant change in mortality on the one hand and our expectation of decreasing mortality on the other: erroneous findings, misguided perceptions about the effectiveness of interventions, or incorrect implementation of interventions.

ERRONEOUS FINDINGS

A change in “patient mix” over time is a plausible possibility for erroneous findings. Nurses and physicians feel that the people they care for and treat are becoming more severely ill. The workload connected with the individual patient is rising, and so does the number of hospital admissions. Outpatient clinics are growing at a rate of approximately 2% per year. Part of this growth could be due to handling less diseased patients as outpatients. Accordingly, more severely diseased patients are admitted to hospital wards. This would raise mortality. But improved treatments keep the mortality at a constant level. Therefore, no net change in mortality is observed.

The patient mix could be influenced by diagnostic drift. Thirty years ago the diagnoses of “non-alcoholic steatohepatits” and “non-alcoholic fibrosis and cirrhosis” were rarely used. These diagnoses have become trendy over the years.10 This may have moved the less severely diseased patients from the alcoholic cirrhosis group to the “new” diagnostic entities. Studies on the “new” non-alcoholic liver diagnoses rarely exclude alcohol problems by adequate means,11–14 so why should clinical practice?

Roberts and colleagues1 may have chosen the “wrong” sampling unit? During the past decades population based liver cirrhosis mortality rates have increased significantly in England, in contrast with other EU countries where it is falling.15 The increase in alcohol consumption may lead to increased mortality rates. This could impact on the patient mix and the findings. However, the findings of Roberts and colleagues1 concur with data from other regions of England16 and from Denmark.17

Roberts and colleagues1 used administrative discharge data for their identification of cases. Diagnostic discharge data are not entirely accurate and liver cirrhosis may have been misclassified in 5–10% of cases, according to the Danish experience.18 Such misclassification however would not explain the lack of improvement in liver cirrhosis mortality unless one could point to a systematic change connecting misclassification over time with changed mortality.

We must consider the possibility of a type II error—no improvement was detected although it actually happened. Nobody can exclude this possibility. The type II error is in fact substantial. Mortality during the period 1994 to 1999 had an odds ratio of 0.90 (95% confidence interval (CI) 0.74–1.09) compared with mortality in the period 1968–1973 (table 4 in Roberts and colleagues1). This corresponds to the finding that mortality may have decreased by 26% or increased by 9%. Only much larger studies, preferably including national or international data, may resolve this issue.

LACK OF BENEFICIAL EFFECT OF INTERVENTIONS CONSIDERED TO BE EFFECTIVE

The second major cause for the contrast between no significant improvement in mortality on the one hand and our expectation of improvements in mortality due to new methods for prevention, diagnosis, treatment, and care on the other is misguided expectations. Could it be that there has in reality been no improvement in mortality during the last 30 years?1

We have no randomised clinical trials demonstrating that cirrhosis mortality can be significantly decreased by liver transplantation. However, we have cohort studies and matched controlled and simulated studies suggesting that this may be so, but these analyses only point to the fact that Child class C patients may have a gain in survival.2,19 Furthermore, less than 25 Child class C patients undergo liver transplanted per year in the Oxford region. This number could not influence the statistics for a whole region.

Endoscopic banding in the primary prevention of variceal bleeding may prevent bleeding but endoscopic banding does not seem to have significant effects on mortality.20 Beta blockers are also recommended for primary prevention3 but we have been unable to demonstrate any significant effect of beta blockers on mortality in high quality trials (Chen W et al, unpublished observations).

Terlipressin and endoscopic interventions may significantly decrease mortality in patients with acute variceal bleeding. But we still lack information on the influence of these interventions on long term mortality.3,21,22

Prevention of rebleeding from varices with beta blockers, endoscopic measures, or transjugular intrahepatic portosystemic stent shunt (TIPS) may have significant effects on mortality but the results are modest.3,23–25 TIPS may remove more ascites but cause more hepatic encephalopathy and does not seem to have significant effects on mortality.26

Much marketing has gone into interventions for chronic hepatitis B and chronic hepatitis C. We do not have any firm knowledge on how interferons affect mortality in patients with chronic hepatitis B.27 Lamivudine seems to affect the clinical course in patients with chronic hepatitis B and advanced liver disease.28 However, we have no convincing evidence showing a significant effect of lamivudine28 on the mortality of chronic hepatitis B patients. The situation for patients with chronic hepatitis C is not much better. Combination therapy with interferon and ribavirin seems to be able to reduce the composite outcome measure of cirrhosis, hepatocellular carcinoma, and death.29 Combination therapy significantly reduced the composite outcome measure in all 9991 patients entered into 72 randomised clinial trials (relative risk 0.49 (95% CI 0.25–0.96; number needed to treat to benefit one patient 419 (95% CI 290–4523)) but not in naive, relapsers, or non-responders individually.29 Furthermore, we found no significant effect of combination therapy on mortality as an isolated outcome.29

Antibiotics are recommended for preventing and treating complications of cirrhosis.3,7–9 Although antibiotics seem to reduce short term mortality we urgently need data on their influence on long term mortality.

INCORRECT IMPLEMENTATION

If the explanation that the interventions do not work is unpalatable, then try this: the interventions worked only a little in clinical research but were incorrectly applied in clinical practice.

We recently assessed the degree of concurrence between research evidence and clinical practice in Denmark.30,31 We evaluated the agreement between research evidence in Cochrane Hepato-Biliary Group systematic reviews32 and reported on the use of clinical interventions for typical patients presenting no contraindications. The Cochrane Hepato-Biliary Group had completed 28 systematic reviews on 36 interventions that were available in Denmark in 2002. Based on the reviews, three interventions with significant beneficial effects on clinical outcomes were classified as “evidence based” (n-acetylcysteine for paracetamol overdose,33 terlipressin for bleeding oesophageal varices,21 and antibiotics for patients with cirrhosis and gastrointestinal bleeding7) whereas 19 were classified as “possibly evidence based” and 14 as “not evidence based”. Questionnaires on reported use and perceived intervention effects were mailed to senior physicians practising in Danish hospitals and being responsible for the treatment of liver patients. The proportion of physicians who reported that they never used the three evidence based interventions varied considerably (2%, 57%, and 62%, respectively). The perceived intervention effect, duration of clinical experience, employment as head of department, and university hospital employment were significant predictors of more frequent use of evidence based interventions. Physicians also reported that they used the interventions that were not evidence based more often if they were employed at a university hospital.

So we observed considerable disagreements between research evidence and reported clinical use in Denmark. Although I have no data to prove it, similar or other mechanisms in Oxford could explain incorrect implementation of interventions.

WHAT TO DO NOW?

As always, when things do not add up more than one thing may be wrong. Could it be a combination of erroneous findings, misguided expectations, and incorrect implementation? The findings in the study of Roberts and colleagues1 as well as the increased liver cirrhosis mortality rates in England over time—in contrast with other countries—call for further epidemiological studies in the UK and abroad. In addition to one year mortality, these studies should also examine five and 10 year mortality changes over time.

We may also need to adjust our expectations to the intervention effects. May be the interventions we use are not as effective as we imagine. We therefore urgently need to develop more effective interventions. In addition to finding new interventions for alcoholic liver cirrhosis, for example,34–37 we must develop preventive measures for the deadly consequences of the increasing alcohol problems in our societies. We also need to scrutinise the beneficial and harmful effects of the intervention we employ in daily clinical practice. In order to accomplish these developments we must become much better in collaborating. Through collaboration we can conduct much larger randomised clinical trials carried out with much better methodology.38–43

We also need more public support for clinical research and possibly less industry involvement.44,45 Finally, we need full transparency in clinical research with publication of and public access to all protocols, protocol amendments, and clinical data.46

Finally, all hospitals and departments should regularly check their clinical practices and clinical guidelines. We need collaboration on getting research into clinical practice. All departments need a team of systematic reviewers who are able to conduct high quality systematic reviews.47 Only by being able to do systematic reviews themselves will they become sufficiently critical of meta-analyses and the so-called “systematic reviews” carried out by others. Furthermore, such activities could benefit the systematic reviewers as well as their departments.48

Conflict of interest: None declared.

REFERENCES

  • 1.Roberts SE, Goldacre MJ, Yeates D. Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999. Gut 2005;54:1615–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Neuberger J. Developments in liver transplantation. Gut 2004;53:759–68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Samonakis DN, Triantos CK, Thalheimer U, et al. Management of portal hypertension. Postgrad Med J 2004;80:634–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167–76. [DOI] [PubMed] [Google Scholar]
  • 5.Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857–61. [DOI] [PubMed] [Google Scholar]
  • 6.Pawlotsky JM, McHutchison JG. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls, Summary of an AASLD hepatitis single topic conference, Chicago, IL, 27 February–1 March 2003. Hepatology 2004;39:554–67. [DOI] [PubMed] [Google Scholar]
  • 7.Soares-Weiser K, Brezis M, Tur-Kaspa R, et al. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. The Cochrane Database of Systematic Reviews 2002, issue 2. Oxford: Update Software, 2002, art. No CD002907. [DOI] [PubMed]
  • 8.Soares-Weiser K, Brezis M, Leibovici L. Antibiotics for spontaneous bacterial peritonitis in cirrhotics. The Cochrane Database of Systematic Reviews 2001, issue 3. Oxford: Update Software, 2001, art. No CD002232. [DOI] [PubMed]
  • 9.Thalheimer U, Triantos CK, Samonakis DN, et al. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005;54:556–63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005;50:171–80. [DOI] [PubMed] [Google Scholar]
  • 11.Nielsen SD, Gluud C. Physicians’ information about alcohol problems at hospitalisation of alcohol misusers. Alcohol Alcohol 1992;27:659–65. [PubMed] [Google Scholar]
  • 12.Nielsen SD, Storgaard H, Moesgaard F, et al. Prevalence of alcohol problems among adult somatic in-patients of a Copenhagen hospital. Alcohol Alcohol 1994;29:583–90. [PubMed] [Google Scholar]
  • 13.Storgaard H, Nielsen SD, Gluud C. The validity of the Michigan Alcoholism Screening Test (MAST)—a review. Alcohol Alcohol 1994;29:493–502. [PubMed] [Google Scholar]
  • 14.McCusker MT, Basquille J, Khwaja M, et al. Hazardous and harmful drinking: a comparison of the AUDIT and CAGE screening questionnaires. QJM 2002;95:591–5. [DOI] [PubMed] [Google Scholar]
  • 15.Vass A. Rates of liver cirrhosis rise in England, fall in Europe. BMJ 2001;323:1388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Saunders JB, Walters JR, Davies AP, et al. A 20-year prospective study of cirrhosis. BMJ Clin Res Ed 1981;282:263–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Sørensen HT, Thulstrup AM, Mellemkjar L, et al. Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark. J Clin Epidemiol 2003;56:88–93. [DOI] [PubMed] [Google Scholar]
  • 18.Vestberg K, Thulstrup AM, Sorensen HT, et al. Data quality of administratively collected hospital discharge data for liver cirrhosis epidemiology. J Med Syst 1997;21:11–20. [DOI] [PubMed] [Google Scholar]
  • 19.Poynard T, Naveau S, Doffoel M, et al. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group. J Hepatol 1999;30:1130–7. [DOI] [PubMed] [Google Scholar]
  • 20.Khuroo MS, Khuroo NS, Farahat KL, et al. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 2005;21:347–61. [DOI] [PubMed] [Google Scholar]
  • 21.Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. The Cochrane Database of Systematic Reviews 2003, issue 1. Oxford: Update Software, 2003, art. No CD002147. [DOI] [PubMed]
  • 22.D’Amico G, Pagliaro L, Pietrosi G, et al. Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients. The Cochrane Database of Systematic Reviews 2002, Issue 1. Oxford: Update Software, 2002, art. No CD002233. [DOI] [PubMed]
  • 23.de la Pena J, Brullet E, Sanchez-Hernandez E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005;41:572–8. [DOI] [PubMed] [Google Scholar]
  • 24.Sauer P, Hansmann J, Richter GM, et al. Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial, Endoscopy 2002;34:690–7. [DOI] [PubMed] [Google Scholar]
  • 25.Escorsell A, Banares R, Garcia-Pagan JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002;35:385–92. [DOI] [PubMed] [Google Scholar]
  • 26.Saab S, Nieto JM, Ly D, et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites. The Cochrane Database of Systematic Reviews 2004, issue 3. Oxford: Update Software, 2004, art. No CD004889. [DOI] [PubMed]
  • 27.Colombo M, Donato MF. Prevention of hepatocellular carcinoma. Semin Liver Dis 2005;25:155–61. [DOI] [PubMed] [Google Scholar]
  • 28.Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521–31. [DOI] [PubMed] [Google Scholar]
  • 29.Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C—an updated systematic Cochrane review on 72 randomised clinical trials with 9991 patients. J Hepatol 2005;42 (suppl 2) :201. [Google Scholar]
  • 30.Gluud LL, Kürstein P, Kjellberg J, et al. The size of the gap between research evidence and clinical practice: questionnaire survey on treatment of patients with liver disease. 12th Cochrane Colloquium, Ottawa, Canada, 2–6 October 2004: abstract 129,.
  • 31.Kürstein P, Gluud LL, Willemann M, et al. Agreement between reported use of interventions for liver diseases and research evidence in Cochrane systematic reviews. J Hepatol 2005; (in press). [DOI] [PubMed]
  • 32.Gluud C, Als-Nielsen B, D’Amico G, et al. The Cochrane Hepato-Biliary Group. About The Cochrane Collaboration. Collaborative Review Groups (CRGs)) 2005, Issue 2. Oxford: Update Software, 2005, art. No, LIVER.
  • 33.Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdoses. The Cochrane Database of Systematic Reviews 2002, issue 3. Oxford: Update Software, 2002, art. No CD003328. [DOI] [PubMed]
  • 34.Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. The Cochrane Database of Systematic Reviews 2003, issue 1. Oxford: Update Software, 2003, art. No CD003045. [DOI] [PubMed]
  • 35.Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. The Cochrane Database of Systematic Reviews 2005, issue 2. Oxford: Update Software, 2005, art. NoCD002148. [DOI] [PMC free article] [PubMed]
  • 36.Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. The Cochrane Database of Systematic Reviews 2001, issue 4. Oxford: Update Software, 2001, art. No CD002800.
  • 37.Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. The Cochrane Database of Systematic Reviews 2001, issue 4. Oxford: Update Software, 2001, art. No CD002235. [DOI] [PubMed]
  • 38.Gluud C, Nikolova D. Quality assessment of reports on clinical trials in Journal of Hepatology. J Hepatol 1998;29:321–7. [DOI] [PubMed] [Google Scholar]
  • 39.Kjærgard LL, Nikolova D, Gluud C. Randomized clinical trials in hepatology—predictors of quality. Hepatology 1999;30:1134–8. [DOI] [PubMed] [Google Scholar]
  • 40.Kjaergard LL, Frederiksen S, Gluud C. Validity of randomized clinical trials in Gastroenterology from 1964–2000. Gastroenterology 2002;122:1157–60. [DOI] [PubMed] [Google Scholar]
  • 41.Kjaergard LL, Gluud C. Funding, disease area, and internal validity of hepato-biliary randomized clinical trials. Am J Gastroenterol 2002;97:2708–13. [DOI] [PubMed] [Google Scholar]
  • 42.Gluud C. Trials and errors in clinical research. Lancet 1999;354:siv59. [DOI] [PubMed] [Google Scholar]
  • 43.Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982–9. [DOI] [PubMed] [Google Scholar]
  • 44.Als-Nielsen B, Chen W, Gluud C, et al. Association of funding and conclusions in randomised drug trials. A reflection of treatment effect or adverse events? JAMA 2003;290:921–8. [DOI] [PubMed] [Google Scholar]
  • 45.House of Commons Health Committee. The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004–05. 2005. http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 23 August 2005).
  • 46.Krleza-Jeric K, Chan A-W, Dickersin K, et al. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (Part 1). BMJ 2005;330:956–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 (updated March 2005). The Cochrane Library, issue 2. Chichester, UK: John Wiley and Sons, Ltd, 2005.
  • 48.Patsopoulos NA, Analatos AA, Ioannidis JP. Relative citation impact of various study designs in the health sciences. JAMA 2005;293:2362–6. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES